ClinicalTrials.gg
CompletedNCT03251729COLORSUpdated Apr 19, 2024

Cerclage On LOw Risk Singletons: Cervical Cerclage for Prevention of Spontaneous Preterm Birth in Low Risk Singleton Pregnancies With Short Cervix

A Phase 4 interventional study of Cervical cerclage and Vaginal progesterone in Premature Birth, sponsored by Thomas Jefferson University. Completed at 3 sites in 2 countries. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-19.

Sponsored by Thomas Jefferson University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 120 studies in Premature Birth with a site in Italy — 28 open to participants now, 31 under way, none of them phase 3. Premature Birth · Italy.

Enrollment
45th of 82
93 · median 100
Started
2017
with 5 others
Phase 4
7 of 120
none open now
Registered
47th of 120
by date

Among the 120 studies in Premature Birth with a site in Italy, this one is the 45th largest by enrollment of the 82 interventional ones that give a count, is one of 6 that started in 2017, is one of 7 in phase 4, and was the 47th registered.

Premature Birth

2,556 studies on the registry are indexed under Premature Birth; 503 are open to participants now.

Browse Premature Birth studies →

Open to participants now

28 of the 120 studies in Premature Birth with a site in Italy are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 317 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 225 (71%) stop at 75 or younger; 242 take children under 18; 104 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Premature Birth with a site in Italy, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the efficacy of cervical cerclage in prevention of spontaneous preterm birth in singleton pregnancies with a short transvaginal cervical length (\<=25mm) and without prior spontaneous preterm birth

Read the detailed description

Singleton pregnancies between 18 0/7 to 23 6/7 weeks without a prior spontaneous preterm birth found to have a short transvaginal ultrasound cervical length (\<=25mm) and meeting all other eligibility criteria will be randomized to either cervical cerclage or control (no cerclage). Aside from cerclage placement, management of included women will be the same including recommendation for daily vaginal progesterone 200mg suppository or 90mg gel from randomization until 36 6/7 weeks. The primary outcome will be the incidence of spontaneous preterm birth \<35 weeks

03

Conditions studied

  • Premature Birth

Browse trials for

Keywords

  • cerclage, preterm birth, short cervix
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 year old or older
  • Singleton pregnancy
  • No prior SPTB or second trimester losses between 160 and 366 weeks
  • TVU CL ≤25mm between 180 and 236 weeks

Exclusion criteria

Exclusion Criteria:

  • Multiple pregnancy
  • Prior SPTB or second trimester losses between 160 and 366 weeks
  • Cerclage in situ
  • Painful regular uterine contraction and/or preterm labor
  • Rupture membranes
  • Major fetal anomaly or aneuploidy
  • Active vaginal bleeding
  • Placenta previa and/or accreta
  • Cervical dilation >1.0 cm and/or visible membranes by pelvic exam
  • Suspicion of chorioamnionitis
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Cerclage

    Cervical cerclage placement along with vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.

    Procedure: Cervical cerclage · Drug: Vaginal progesterone

  • Other
    Control

    Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.

    Drug: Vaginal progesterone

Interventions

  • ProcedureCervical cerclage

    Transvaginal cervical cerclage placed between 18 0/7 - 23 6/7 weeks

  • Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks

06

What researchers measure

Primary outcomes

  1. Preterm birth <35 weeks

    Incidence of spontaneous preterm birth less than 35 weeks

    Time frame: At delivery

Secondary outcomes

  1. Preterm birth <37 weeks, <34 weeks, <32 weeks, <28 weeks, <24 weeks

    Time frame: At delivery

  2. Mean gestational age at delivery

    Time frame: At delivery

  3. Histologically proven clinical chorioamnionitis

    Time frame: At delivery

  4. Neonatal outcomes: birth weight

    Time frame: At delivery

  5. Neonatal outcomes: low birth weight (<2500g),

    Time frame: At delivery

  6. Neonatal outcomes: admission to intensive care nursery

    Time frame: At delivery

  7. Neonatal outcomes: length of neonatal hospital admission

    Time frame: at least 30 days after delivery, up to 6 months after delivery

  8. Neonatal outcomes: respiratory distress syndrome

    Time frame: at least 30 days after delivery, up to 6 months after delivery

  9. Neonatal outcomes: IVH grade 3 or 4

    Time frame: at least 30 days after delivery, up to 6 months after delivery

  10. Neonatal outcomes: retinopathy of prematurity

    Time frame: at least 30 days after delivery, up to 6 months after delivery

  11. Neonatal outcomes: bronchopulmonary dysplasia

    Time frame: at least 30 days after delivery, up to 6 months after delivery

  12. Neonatal outcomes: neonatal mortality

    Time frame: 28 days after delivery

07

Study locations

3 sites
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • University of Naples Federico II
    Naples, Italy
  • University Cattolica del S. Cuore
    Rome, Italy
08

References and documents

Publications

  • Berghella V, Ciardulli A, Rust OA, To M, Otsuki K, Althuisius S, Nicolaides KH, Roman A, Saccone G. Cerclage for sonographic short cervix in singleton gestations without prior spontaneous preterm birth: systematic review and meta-analysis of randomized controlled trials using individual patient-level data. Ultrasound Obstet Gynecol. 2017 Nov;50(5):569-577. doi: 10.1002/uog.17457. Epub 2017 Oct 5. PubMed 28295722 ↗

Individual participant data

Plan to share: Yes — IPD will be shared upon completion of appropriate data sharing agreements

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 1yr after study completion

Access criteria: IPD will be shared upon completion of appropriate data sharing agreements

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Feb 2024, 76 months.

Of 54 non-industry phase 4 interventional studies under Premature Birth, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 60. This study's 76 months is above that.

Counting every sponsor, half of 54 studies reached it within 25 months; a quarter within 13 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2017
First posted
Aug 16, 2017
StartActual
Sep 22, 2017
Primary completionActual
Feb 20, 2024
CompletionActual
Feb 20, 2024
Last update
Apr 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03251729
Responsible party
Sponsor
First posted
Aug 16, 2017
Start date
Sep 22, 2017
Primary completion
Feb 20, 2024
Completion
Feb 20, 2024
Last update
Apr 19, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion